PDF(Pubmed)
Abstract：
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive and therapy-resistant form of breast cancer with a significant economic burden on patients and healthcare systems. Therefore, we completed a systematic review to classify and synthesize the literature on the direct and indirect costs of TNBC.
METHODS: Databases including ISI Web of Science, Scopus, PubMed, and Google Scholar were searched for all related articles assessing the economic burden of TNBC from 2010 until December 2022. The quality and eligibility assessments were done accordingly. We adjusted all costs to January 2023 $US.
RESULTS: From 881 records, 15 studies were eligible. We found that studies are widely disparate in the timetable, study design, patient populations, and cost components assessed. The annual per-patient direct costs of metastatic TNBC (mTNBC) were about $24,288 to $316,800. For early TNCB patients (eTNBC) this was about $21,120 to $105,600. Cancer management anticancer therapy costs account for the majority of direct costs. Along with an increase in cancer stage and line of therapy, healthcare costs were increased. Moreover, the indirect costs of patients with mTNBC and eTNBC were about $1060.875 and about $186,535 for each patient respectively.
CONCLUSIONS: The results showed that the direct and indirect costs of TNBC, mainly those of mTNBC, were substantial, suggesting attention to medical progress in cancer prognosis and therapy approaches.
METHODS: Databases including ISI Web of Science, Scopus, PubMed, and Google Scholar were searched for all related articles assessing the economic burden of TNBC from 2010 until December 2022. The quality and eligibility assessments were done accordingly. We adjusted all costs to January 2023 $US.
RESULTS: From 881 records, 15 studies were eligible. We found that studies are widely disparate in the timetable, study design, patient populations, and cost components assessed. The annual per-patient direct costs of metastatic TNBC (mTNBC) were about $24,288 to $316,800. For early TNCB patients (eTNBC) this was about $21,120 to $105,600. Cancer management anticancer therapy costs account for the majority of direct costs. Along with an increase in cancer stage and line of therapy, healthcare costs were increased. Moreover, the indirect costs of patients with mTNBC and eTNBC were about $1060.875 and about $186,535 for each patient respectively.
CONCLUSIONS: The results showed that the direct and indirect costs of TNBC, mainly those of mTNBC, were substantial, suggesting attention to medical progress in cancer prognosis and therapy approaches.
摘要：
背景：三阴性乳腺癌（TNBC）是一种侵袭性且对治疗具有抗性的乳腺癌形式，对患者和医疗保健系统具有重大的经济负担。因此,我们完成了系统综述,对有关TNBC直接成本和间接成本的文献进行了分类和综合.
方法：包括ISIWebofScience、Scopus,PubMed,和GoogleScholar搜索了所有评估TNBC从2010年到2022年12月经济负担的相关文章。相应地进行了质量和资格评估。我们将所有费用调整为2023年1月$US。
结果：来自881条记录，15项研究合格。我们发现研究在时间表上大相径庭，研究设计，患者群体，和评估的成本组成部分。每年每位患者的转移性TNBC（mTNBC）直接费用约为$24,288至$316,800。对于早期TNCB患者（eTNBC），约为21,120至105,600美元。癌症管理抗癌治疗费用占直接成本的大部分。随着癌症分期和治疗路线的增加，医疗费用增加。此外，mTNBC和eTNBC患者的间接成本分别为每名患者约1060.875美元和约186,535美元.
结论：结果表明，TNBC的直接和间接成本，主要是mTNBC的，是实质性的，建议关注癌症预后和治疗方法的医学进展。
方法：包括ISIWebofScience、Scopus,PubMed,和GoogleScholar搜索了所有评估TNBC从2010年到2022年12月经济负担的相关文章。相应地进行了质量和资格评估。我们将所有费用调整为2023年1月$US。
结果：来自881条记录，15项研究合格。我们发现研究在时间表上大相径庭，研究设计，患者群体，和评估的成本组成部分。每年每位患者的转移性TNBC（mTNBC）直接费用约为$24,288至$316,800。对于早期TNCB患者（eTNBC），约为21,120至105,600美元。癌症管理抗癌治疗费用占直接成本的大部分。随着癌症分期和治疗路线的增加，医疗费用增加。此外，mTNBC和eTNBC患者的间接成本分别为每名患者约1060.875美元和约186,535美元.
结论：结果表明，TNBC的直接和间接成本，主要是mTNBC的，是实质性的，建议关注癌症预后和治疗方法的医学进展。
